Key Takeaways BMY stock lags with a 16.3% YTD drop, trailing the industry, sector, and S&P 500 in 2025. Generic hits to top drugs and pipeline setbacks have weighed on investor sentiment despite strong Q1. Newer drugs like Reblozyl, Breyanzi, and Opdualag help stabilize revenues and diversify BMY's portfolio.The first half of 2025 has been topsy-turvy for Bristol Myers (BMY) . Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also underpe ...